SIGA Technologies, Inc. (SIGA) shares tanked hard on news that a Delaware court of Chancery had ruled in favour of PharmAthene (PIP) in a dispute involving SIGA‘s smallpox drug ST-246. 50% of the net profits that SIGA will be achieving from sales of ST-246 awarded to PharmAthene for the next ten years. Harsh decision, isn’t it? […]